26 results about "Rosuvastatin" patented technology

The present invention provides a pharmaceutical composition comprising a) a first phase comprising rosuvastatin, and b) a second phase comprising acetylsalicylic acid, wherein the first phase comprising rosuvastatin is in the form of a coated tablet, and the second phase comprising acetylsalicylic acid is in the form of granules; said pharmaceutical composition solves a set of significant technological challenges due to the physicochemical properties and difference in dosage of each drug. The pharmaceutical composition of the present invention is stable, and also has a comparative bioavailability equivalent to that of the co-administered monodrugs, so that the composition is safe and effective in the treatment of hyperlipidemias and in the prevention of at least one cardiovascular disease. The invention is also directed to a process for manufacturing the pharmaceutical composition.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs.

The present invention relates to a composition for preventing, alleviating or treating metabolic diseases, the composition comprising a rosuvastatin and ursodeoxycholic acid conjugate or a pharmaceutically acceptable salt thereof, in which the statin conjugates to an ursodeoxycholic acid transporter and has the effects of function inhibition, cholesterol level reduction, antilipid toxicity, body weight reduction, blood lipid reduction, fatty liver alleviation, inflammation alleviation, and kidney damage alleviation. The composition, in the form of a single formulation, has the characteristics of maintaining the therapeutic effects of rosuvastatin and ursodeoxycholic acid while reducing the side effects of existing statins, and thus can be widely used as a substitute for complex formulations in the treatment of metabolic diseases.

The present disclosure provides method of administering sotorasib to a patient, e.g., a patient with a cancer comprising a KRAS G12C mutation, wherein the patient is further in need of treatment with a breast cancer resistance protein (BCRP) substrate. e.g., rosuvastatin.

The utility model relates to the technical field of rosuvastatin production equipment, and discloses a raw material crushing mechanism for rosuvastatin intermediate production. Comprising a grinding roller, a grinding cylinder, a supporting frame, a conical feeding opening, a discharging pipe, a conveying chamber, a high-pressure air pipe, a powder conveying pipe, a first separating cylinder, a second separating cylinder, a vacuum feeding machine, a conduction pipe, a screening net cover, a filter, a material returning opening and a material collecting barrel. According to the crushing mechanism, raw materials are ground through the grinding roller and the grinding cylinder, the particle diameter is gradually reduced, then the ground raw materials are screened through the first separation cylinder and the second separation cylinder, raw material powder meeting the standard is collected and stored, and raw material powder not meeting the standard enters the grinding cylinder again to be ground; the fineness and the reaction efficiency of the raw materials are improved, and the production of the rosuvastatin intermediate is facilitated.

The present invention relates to a pharmaceutical combination preparation, which comprises all of ezetimibe, rosuvastatin and empagliflozin as active ingredients, and thus can be administered as a single drug, and not through co-administration, in the simultaneous treatment of dyslipidemia and diabetes, thereby increasing patient dosing convenience, minimally affecting dissolution between drugs, ensuring biological equivalence, and providing excellent stability of the active ingredients.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

The present invention provides a pharmaceutical composition comprising a) a first phase comprising rosuvastatin, and b) a second phase comprising acetylsalicylic acid, wherein the first phase comprising rosuvastatin is a coated tablet and the second phase comprising acetylsalicylic acid is a granule; This pharmaceutical composition solves a set of important technological challenges due to the physicochemical properties and the difference in dosage of each drug. The pharmaceutical composition of the present invention is stable and, moreover, has comparable bioavailability to the single-drug combinations administered concomitantly, such that the composition is safe and effective in the treatment of hyperlipidemia and in the prevention of at least one cardiovascular disease. The invention also relates to a manufacturing process for the pharmaceutical composition.

A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.

The invention relates to a stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.

The invention belongs to the technical field of biological medicines, and relates to a traditional Chinese medicine micromolecule composition and application thereof in preparation of medicines for treating metabolism-related fatty liver diseases. Through combined use of two or more of naringin, sophoriol, 8-isopentenyl naringenin and butene-7-O-beta-D-glucopyranoside, especially combined use of the four components, weight gain of MAFLD mice induced by high-fat diet / high-fat and high-sugar diet can be significantly reduced, lipid accumulation in the liver is reduced, and the weight loss of the mice is reduced. The insulin resistance is relieved, and the hepatocyte injury is improved. The composition can improve blood biochemical indexes related to lipid metabolism, relieve oxidative stress, increase fat consumption and improve a metabolic mode, and the effect is superior to that of a western medicine rosuvastatin positive control group and that of a western medicine rosuvastatin single use group.

The utility model discloses an extraction layering reaction kettle for producing a rosuvastatin intermediate, which relates to the technical field of medicine extraction and comprises a sealing barrel and a centrifugal barrel, a conveying pipe is arranged on the sealing barrel, the centrifugal barrel is rotatably arranged in the sealing barrel, and the conveying pipe is connected with the centrifugal barrel. A driving assembly used for driving the centrifugal barrel to rotate is arranged on the sealing barrel, a discharging pipe penetrating through the sealing barrel is arranged at the bottom of the centrifugal barrel, a control valve is fixedly connected to the discharging pipe, and an air pressure balance assembly is arranged at the top of the sealing barrel. When the centrifugal machine is used, the motor can drive the connecting disc to rotate, the rotating connecting disc drives the centrifugal barrel to rotate through the connecting rod, so that a layered solution in the centrifugal barrel generates centrifugal force, and due to the fact that the mass of water is large, the edge of a rotating water layer can gradually rise upwards along the inner wall of the centrifugal barrel, and meanwhile the middle of the water layer is sunken. Therefore, the contact area of the water layer and the toluene layer is increased, and the extraction efficiency is improved.

This invention discloses a process for synthesizing rosuvastatin acetone tert-butyl ester, comprising the following steps: First, compound I is dissolved in an organic solvent, compound II is added, and the reaction is stirred at room temperature. The reaction is monitored by HPLC. After the reaction is complete, the product is separated to obtain compound III. Second, a palladium catalyst is added to the organic solvent, stirred and mixed evenly, and then compound III and compound IV are added and stirred under the action of the palladium catalyst to obtain compound V. The advantages of this invention are: mild reaction conditions, the entire process is carried out at room temperature, eliminating the need for harsh conditions such as high temperature and high pressure, reducing energy consumption and equipment requirements, and making it suitable for industrial-scale production; excellent stereoselectivity, using a palladium-catalyzed reselective Heck reaction to replace the traditional Witting and Julia olefin reactions, avoiding stereoisomer byproducts, and resulting in higher purity of the target product; fewer byproducts and simpler separation.

The invention belongs to the technical field of biological medicine, and particularly relates to a targeted bionic nano-drug loaded with tanshinone IIA and rosuvastatin as well as a preparation method and application of the targeted bionic nano-drug loaded with the tanshinone IIA and the rosuvastatin. And wrapping the outer layer of the loaded polylactic acid-glycolic acid copolymer with a macrophage membrane, and modifying the surface of the macrophage membrane by using the phosphatidylated hyaluronic acid. According to the targeted bionic nano-drug system, the polylactic acid-glycolic acid copolymer is used for loading two drugs at the same time, inhibition of endothelial cell mesenchymal transition by tanshinone IIA and regulation of macrophage lipid metabolism by rosuvastatin are organically combined, and the effect of combined treatment of atherosclerosis is achieved.

The invention relates to a stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.

The invention provides a low-matrix-effect LC-MS / MS method for ultra-trace detection of rosuvastatin in serum, and belongs to the technical field of analysis. Comprising the following steps: (1) preparing a standard stock solution and a standard curve working solution of a target object to be detected; (2) treating the blood sample to obtain a detection sample; and (3) detecting the standard curve working solution by using HPLC-MS / MS, fitting to obtain a standard curve equation corresponding to the target object to be detected, and detecting the detection sample by using HPLC-MS / MS to obtain the content of the target object to be detected in the detection sample. According to the method, the limit of detection (LOD) is about 1.26 ng / m, the limit of quantitation (LOQ) is about 4.19 ng / ml, and the inter-batch precision (RSD) is less than 15%, so that the reproducibility of the method and the stability of a result are ensured.

The invention discloses a conjugate HA-RS obtained by direct esterification of hydroxyls and carboxyls in hyaluronic acid and derivatives thereof, rosuvastatin and prodrug structures thereof, and also discloses a nano-micelle HA-RS-NPs formed by the conjugate, and a preparation method and application of the nano-micelle HA-RS-NPs. The hyaluronic acid and hyaluronic acid derivative loaded rosuvastatin and prodrug nano-micelle disclosed by the invention can be specifically combined to vulnerable plaque cells, and can realize stable and continuous release of drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to an ROS response type liposome composite material and a preparation method and application thereof.The ROS response type liposome composite material is prepared by jointly loading alkannin and rosuvastatin to liposome modified by an ROS sensitive connecting substance DSPE-TK-PEG2000, further wrapping a biomimetic membrane on the outer layer, and preparing the ROS response type liposome composite material. The ROS response type liposome composite material is obtained. According to the present invention, by using the ROS response design characteristic, the specific aggregation and the response type release of the drug at the diseased region are achieved, the blood circulation half-life period of the drug is effectively prolonged, and the anti-atherosclerosis effects of the shikonin and the rosuvastatin with two different mechanisms are combined so as to achieve the effect of effective treatment of the homocysteine induced atherosclerosis.

The present disclosure provides a combination therapy for treating a liver disease or disorder and / or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.

The present invention relates to a composition for cancer prevention, comprising a statin-based drug as an active ingredient, and disclosed is that a statin drug known for hyperlipidemia treatment may effectively prevent cancer progression. More specifically, a novel use of rosuvastatin is provided so as to enable providing a composition for multiple myeloma (MM) prevention for inhibiting progression from monoclonal gammopathy of undetermined significance (MGUS) to MM. In addition, the composition may exhibit a greater tumor growth inhibition effect when bortezomib and rosuvastatin are co-administered compared to when each medicine is administered alone.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.

The present invention relates to a rapidly disintegrating tablet that can disintegrate in the buccal cavity upon contact with saliva in less than 1 minute, preferably in less than 40 seconds. The tablet comprises rosuvastatin or pharmaceutically acceptable salts thereof, as well as a combination of excipients that include at least one disintegrating agent and at least one diluent agent. The present invention is based on enhancing the disintegration and dissolution of the drug for oral administration.

The present application relates to a kind of traditional Chinese medicine compositions, including the following weight parts of preparation raw materials: Huanglian 15~20 parts, Fashi 15~18 parts, Gualoupi 30~45 parts, Juhong 10~15 parts, Danshen 15~20 parts, Baishu 15~20 parts.The traditional Chinese medicine composition prepared in the present application has obvious effect of resisting non-alcoholic fatty liver disease (NAFLD), compared with Rosuvastatin, can further improve the lipid accumulation and balloon-like change of liver, improve the level of triglyceride (TG), cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) in blood fat, reduce liver damage index glutamic-pyruvic transaminase (ALT), inhibit the expression of inflammatory factors (TNF-alpha and IL-1beta).At the same time, the body weight of NAFLD mouse can be significantly reduced, glucose tolerance can be improved, insulin sensitivity can be improved, insulin resistance can be reduced, and the efficacy of regulating intestinal flora and increasing the abundance of intestinal Akkermansia bacteria can be achieved.